Thus, EGFR tyrosine kinase inhibitors, such as Erlotinib 49, and EGFR monoclonal antibodies, such as cetuximab 50, have investigated the antitumor activity against human oral cancer. Here, EGFR is linked to lip and oral cavity carcinoma.